Insights from experimental models of pulmonary fibrosis and translational research have significantly advanced understanding of these processes and are reviewed in this article, together with current therapeutic advances and future directions.
Abstract
Fibrotic interstitial lung diseases (fILDs) encompass a heterogeneous group of interstitial lung diseases (ILDs) and may arise from persistent inflammation caused by systemic disease or environmental exposures. Idiopathic pulmonary fibrosis (IPF), the prototypical fILD, is characterized by progressive fibrosis, limited inflammation, and a high mortality rate. In contrast, other fILDs display variable contributions of fibrosis and inflammation that are only partially determined by the underlying diagnosis. Within most fILDs, a broad spectrum of disease phenotypes can be observed.Inflammation and fibrosis are not discrete, sequential events but rather dynamically intertwined processes. The nature and relative importance of these interactions vary according to the underlying etiology. Inflammation can function as both a driver and a consequence of fibrotic remodeling, establishing self-perpetuating feed-forward loops, yet also playing a role in fibrosis resolution and control. As therapeutic strategies for predominantly fibrotic versus inflammatory ILDs differ substantially, improved understanding of the pathomechanisms that drive fibrosis is essential for optimizing personalized treatment approaches.Fibrotic and inflammatory signaling pathways show considerable overlap, and their interaction is central to disease initiation and progression. Elucidating the mechanisms that govern cellular responses to diverse injurious stimuli provides an opportunity to refine patient stratification and tailor therapies to improve outcomes. Insights from experimental models of pulmonary fibrosis (PF) and translational research have significantly advanced our understanding of these processes and are reviewed in this article, together with current therapeutic advances and future directions.
Interstitial lung abnormalities (ILAs) are incidental, non-dependent parenchymal abnormalities detected on chest computed tomography (CT) in individuals without a diagnosis of interstitial lung disease (ILD). Once regarded as non-specific or age-related findings, ILAs are increasingly recognized as clinically relevant...
B. Selvarajah, Durdica Buconjic, Richard J. Hewitt· Frontiers in Medicine· 0 citations
Background Interstitial lung diseases (ILDs) are a heterogeneous group of disorders in which epithelial injury, inflammation and fibrosis lead to progressive loss of lung function. Several ILDs other than idiopathic pulmonary fibrosis (IPF), including connective tissue disease-associated ILD (CTD-ILD), fibrotic hyperse...
Mariana Pădureanu, Ileana Marinescu, D. Mitroi et al.· Frontiers in Medicine· 0 citations
A detailed review of elastic fiber biology, the mechanisms by which CF pathophysiology disrupts elastic fiber integrity, the downstream structural and functional consequences, and potential therapeutic avenues targeting elastic fiber preservation or restoration are provided.
Pulmonary fibrosis is a fatal interstitial lung disease characterized by excessive fibroblast proliferation and aberrant deposition of extracellular matrix (ECM), ultimately leading to structural lung destruction and respiratory failure. Neutrophils, as key effector cells of innate immunity, have been increasingly reco...
Zu-Ming Chen, Jin-Yu Tang, Zi-Han Wang et al.· International Immunopharmaco...· 0 citations
Pulmonary fibrosis (PF) encompasses a spectrum of progressive and irreversible interstitial lung diseases characterized by a notably poor prognosis. The principal pathological features of PF include recurrent injury to the alveolar epithelium, aberrant accumulation of extracellular matrix (ECM) components, and disrupti...
Yu-Jie Yang, Sen-Yuan Liu, Shang Wang et al.· Pharmacological Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.